Novartis
146 views | +0 today
Follow
Your new post is loading...
Your new post is loading...
Scooped by 27 Yeast Infection
Scoop.it!

Novartis' omalizumab effective in chronic skin disease

Novartis' omalizumab effective in chronic skin disease | Novartis | Scoop.it
TopNews United States
Novartis' omalizumab effective in chronic skin disease
PMLiVE
Novartis' allergic asthma treatment Xolair could find a new role as a treatment for an allergic skin disease after encouraging results in a phase III trial.
more...
No comment yet.
Scooped by 27 Yeast Infection
Scoop.it!

Why Novartis case will help innovation

Why Novartis case will help innovation | Novartis | Scoop.it
The Supreme Court judgment on Glivec is a blow for a patent regime with a higher threshold of inventiveness (Why Novartis case will help innovation http://t.co/kONwTdzfGw via @thehindu)...
more...
No comment yet.
Scooped by 27 Yeast Infection
Scoop.it!

Data on Novartis Influenza Vaccine

Data on Novartis Influenza Vaccine | Novartis | Scoop.it
Republica
Data on Novartis Influenza Vaccine
Zacks.com
Novartis aims to focus better on its strategic business and hence the company decided to divest its diagnostics business.
more...
No comment yet.
Rescooped by 27 Yeast Infection from Health innovations, mhealth, digital ...
Scoop.it!

Novartis, Pfizer both developing hot new breast cancer treatment drug

Novartis, Pfizer both developing hot new breast cancer treatment drug | Novartis | Scoop.it
Novartis's experimental new breast cancer treatment drug, LEE011, was set to enter final-stage Phase III clinical trials next month.

Via Clara Hamelin
more...
Clara Hamelin's curator insight, November 25, 2013 4:50 PM

ONDON (Reuters) - Novartis is hot on the heels of Pfizer in developing a promising new type of breast cancer drug that analysts believe could generate billions of dollars in annual sales.

The Swiss drugmaker, which has previously kept its research program under wraps, revealed on Friday that its experimental pill LEE011 was set to enter final-stage Phase III clinical trials next month.

Pfizer's rival drug palbociclib - the first in the class - is already in Phase III testing, but Novartis' rapid progress means the U.S. group could face competition sooner than expected. Both drugs are pills and work by blocking two enzymes known as cyclin dependent kinases (CDK) 4 and 6.

The significance of the new targeted approach to fighting cancer was highlighted in April when U.S. regulators granted a "breakthrough therapy" designation to palbociclib, based on impressive results seen in mid-stage trials.

Palbociclib is widely seen by investors as Pfizer's most valuable compound in late-stage development and the company has started several new clinical trials to maximize its potential.

Analysts currently expect annual palbociclib sales of $1.9 billion by 2019, according to consensus estimates compiled by Thomson Reuters Pharma, and some think it could eventually sell $5 billion if it is approved for multiple cancer types.

Because Novartis has not previously revealed mid-stage clinical trial data for LEE011, analysts have not so far modeled sales forecasts for that product.

Scooped by 27 Yeast Infection
Scoop.it!

Long Live Life: Reflecting on the Novartis mission

Long Live Life is a collective expression for what Novartis stands for and believes in as a company -- that normal life is extraordinary and that every day w... (Really Inspiring!
more...
No comment yet.
Scooped by 27 Yeast Infection
Scoop.it!

Novartis sets sights on eliminating leprosy

Novartis sets sights on eliminating leprosy | Novartis | Scoop.it
Novartis sets sights on eliminating leprosy
PMLiVE
Novartis has launched a new strategy to tackle leprosy, with the aim of completely eliminating the disease around the world.
more...
No comment yet.
Scooped by 27 Yeast Infection
Scoop.it!

Pharmaceutical pricing system in need of reform: Novartis Vice Chairman

Pharmaceutical pricing system in need of reform: Novartis Vice Chairman | Novartis | Scoop.it
Daily News Egypt Pharmaceutical pricing system in need of reform: Novartis Vice Chairman Daily News Egypt New regulations for pharmaceuticals registration and pricing are needed to revitalise the sector, according to Salah El Sharkawy, Vice...
more...
No comment yet.
Scooped by 27 Yeast Infection
Scoop.it!

Novartis' MS drug Gilenya tied to rare brain infection - FiercePharma

Novartis' MS drug Gilenya tied to rare brain infection - FiercePharma | Novartis | Scoop.it
Blouin News Blogs Novartis' MS drug Gilenya tied to rare brain infection FiercePharma Novartis' ($NVS) Gilenya, which a consumer watchdog group last year pegged with safety concerns, is again being called into question after a patient taking the...
more...
No comment yet.
Scooped by 27 Yeast Infection
Scoop.it!

Novartis marks 30 year anniversary in transplantation and reinforces continued ... - MarketWatch

Novartis marks 30 year anniversary in transplantation and reinforces continued ... - MarketWatch | Novartis | Scoop.it
Novartis marks 30 year anniversary in transplantation and reinforces continued ...
more...
No comment yet.
Scooped by 27 Yeast Infection
Scoop.it!

Novartis and Regenerex to collaborate on cell therapy research - Zenopa

Novartis and Regenerex to collaborate on cell therapy research - Zenopa | Novartis | Scoop.it
Novartis and Regenerex to collaborate on cell therapy research Zenopa The agreement will allow Novartis to take advantage of Regenerex's novel Facilitating Cell Therapy (FCRx) platform, a haematopoietic stem cell-based technology offering that has...
more...
No comment yet.
Scooped by 27 Yeast Infection
Scoop.it!

Novartis to Host Animal Health Conferences - ThePigSite.com

Novartis to Host Animal Health Conferences - ThePigSite.com | Novartis | Scoop.it
Novartis to Host Animal Health Conferences ThePigSite.com GLOBAL - Novartis AH is organising, together with corresponding researchers working in the area of Colonic Spirochaetal infections, conferences on a three year basis to discuss topics...
more...
No comment yet.
Scooped by 27 Yeast Infection
Scoop.it!

Novartis in good health amid blockbuster boost - This is Scunthorpe

Novartis in good health amid blockbuster boost - This is Scunthorpe | Novartis | Scoop.it
Novartis in good health amid blockbuster boost This is Scunthorpe GRIMSBY pharmaceutical giant Novartis is stepping up production by a whopping 44 per cent, as the number of "blockbuster" drugs created on-site goes from one to three in the coming...
more...
No comment yet.
Scooped by 27 Yeast Infection
Scoop.it!

With new tools, Novartis targets brain disease - Boston Globe

With new tools, Novartis targets brain disease Boston Globe Novartis is returning to an area of medical research that has defeated drug companies time and again over the past decade: diseases of the brain — from depression to Parkinson's — that...
more...
No comment yet.
Scooped by 27 Yeast Infection
Scoop.it!

Novartis reboots brain division

Novartis reboots brain division | Novartis | Scoop.it
Novartis reboots brain division Nature.com When Novartis closed down its conventional drug-discovery programme in Basel, Switzerland, last year (see Nature 480, 161–162; 2011), it was already planning to reopen with an entirely new approach at its...
more...
No comment yet.
Scooped by 27 Yeast Infection
Scoop.it!

Novartis Hosts Competition to Create Novel Mobile Solutions for Heart Failure .

Novartis Hosts Competition to Create Novel Mobile Solutions for Heart Failure . | Novartis | Scoop.it
Novartis Hosts Competition to Create Novel Mobile Solutions for Heart Failure ...
more...
No comment yet.
Scooped by 27 Yeast Infection
Scoop.it!

Novartis Launches COPD Inhalation Capsules in Japan - Drug Discovery & Development

Novartis Launches COPD Inhalation Capsules in Japan - Drug Discovery & Development | Novartis | Scoop.it
Drug Discovery & Development
Novartis Launches COPD Inhalation Capsules in Japan
Drug Discovery & Development
Sosei Group Corp. confirms that Novartis Pharma K.K.
more...
No comment yet.
Rescooped by 27 Yeast Infection from Pharma & Medical Devices
Scoop.it!

Novartis offers patients two new apps

Novartis offers patients two new apps | Novartis | Scoop.it

My NET Manager is an app for patients with neuroendocrine tumors (or NET) to help them manage and learn about their condition. It provides tools for users to track their symptoms, set reminders for treatments, doctor visits, and medication refills, and review and track test results. The app also stores contact information for a patients’ healthcare team and enables the patient to share information with their team. Finally, the app can help NET patients track insurance claims.


Via Richard Meyer
more...
No comment yet.
Scooped by 27 Yeast Infection
Scoop.it!

Novartis Scientists Discover New Drug Target To Treat Malaria - Quick Facts

Novartis Scientists Discover New Drug Target To Treat Malaria - Quick Facts | Novartis | Scoop.it
Science World Report
Novartis Scientists Discover New Drug Target To Treat Malaria - Quick Facts
RTT News
Swiss drugmaker Novartis AG (NVS: Quote) said its scientists have discovered a new drug target for treating malaria.
more...
No comment yet.
Scooped by 27 Yeast Infection
Scoop.it!

Novartis scientists discover new drug for malaria treatment

Science Codex Novartis scientists discover new drug for malaria treatment pharmabiz.com Novartis scientists have discovered a new drug target for treating malaria, which identifies phosphatidylinositol-4 kinase (PfPI4K) as the target of the...
more...
No comment yet.
Rescooped by 27 Yeast Infection from Healthcare: reloaded...
Scoop.it!

In late-stage study, Novartis finds asthma drug effective at reducing itch from hives

In late-stage study, Novartis finds asthma drug effective at reducing itch from hives | Novartis | Scoop.it
Novartis said its drug omalizumab was almost doubly effective as a placebo in improving quality of life for patients with a severe form of hives.

Via Beeyond
more...
Beeyond's curator insight, October 6, 2013 1:52 AM

Impressive result. However... I cannot help thinking that... it tells a bit on how little is understood about the way our body works... "I'll treat your asthma! - Heu? My asthma is the same but my skin is better!". Kind of a...(for once) desirable side effect, right?...

Scooped by 27 Yeast Infection
Scoop.it!

Novartis heart failure drug found to be effective across patient groups - Global Times

Novartis heart failure drug found to be effective across patient groups - Global Times | Novartis | Scoop.it
Novartis heart failure drug found to be effective across patient groups Global Times An experimental drug from Novartis to treat heart failure proved equally effective regardless of the age of patients or whether they had other medical problems,...
more...
No comment yet.
Scooped by 27 Yeast Infection
Scoop.it!

Novartis signs deal to boost cell therapy portfolio - Reuters

Novartis signs deal to boost cell therapy portfolio - Reuters | Novartis | Scoop.it
Economic Times
Novartis signs deal to boost cell therapy portfolio
Reuters
... 2013 1:53am EDT.
more...
No comment yet.
Scooped by 27 Yeast Infection
Scoop.it!

Novartis picks up its development option in $700M rare-disease pact - FierceBiotech

Novartis picks up its development option in $700M rare-disease pact - FierceBiotech | Novartis | Scoop.it
Novartis picks up its development option in $700M rare-disease pact FierceBiotech Novartis ($NVS) has picked up its option on a Phase II-ready therapy for a pair of rare diseases from Sweden's Camarus, forking over a milestone included in their...
more...
No comment yet.
Rescooped by 27 Yeast Infection from Lung Cancer Research Digest
Scoop.it!

FDA seeks to fast track Novartis lung cancer drug

"The U.S. Food and Drug Administration has designated a compound developed by Novartis AG to treat a type of non-small cell lung cancer for fast-track development and review, the Swiss drugmaker said on Friday."


Via Cancer Commons
more...
Cancer Commons's curator insight, March 15, 2013 2:37 PM

U.S. Food and Drug Administration. Mar 15, 2013.

Scooped by 27 Yeast Infection
Scoop.it!

Novartis Ties Up With Regenerex - Zacks.com

Novartis Ties Up With Regenerex - Zacks.com | Novartis | Scoop.it
Novartis Ties Up With Regenerex
Zacks.com
... with privately-held biopharmaceutical company, Regenerex.
more...
No comment yet.